29-Mar-2018

Why GDC-0084 for glioblastoma: Q&A with Kazia CEO Dr James Garner

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

29-Mar-2018

GDC-0084 and glioblastoma multiforme

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing a new therapy called GDC-0084 to treat the rare and deadly brain cancer, glioblastoma multiforme (GBM).

29-Mar-2018

NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

30-Nov-2017

Novogen changes name to Kazia Therapeutics

CommSec's Tom Piotrowski talks with Kazia Executive Director and CEO Dr James Garner about our company name change to Kazia Therapeutics.

20-Nov-2017

Novogen becomes Kazia Therapeutics

Australian biotechnology company, Novogen has announced that it will change its name to Kazia Therapeutics and that it will consolidate its share register, after the overwhelming majority of shareholders voted in favour of the proposed changes at the company's AGM held in Sydney last week.

04-Jul-2017

CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients

CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.

01-May-2017

Dr James Garner, CEO, speaks to Canary Networks investment forum

Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.

30-Jan-2017

CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress

CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.

31-Oct-2016

Sky News Interview – In-licensing of GDC-0084

Novogen Sky News Interview